Zydus receives EIR for the API manufacturing facility at Dabhasa

Zydus Lifesciences Ltd has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara.

This facility underwent an inspection from 21st to 25th April 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as "closed".

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 973.45 as compared to the previous close of Rs. 960.00. The total number of shares traded during the day was 17326 in over 1262 trades.

The stock hit an intraday high of Rs. 975.80 and intraday low of 960.25. The net turnover during the day was Rs. 16809069.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals EIR USFDA APIFacility Dabhasa VAI